Cell therapy commercialization: Streamline your path to cell therapy commercialization

FHS
August 28, 2024
11:18 am

Moving your cell therapy clinical trial beyond Phase I is an exciting time, marking a significant milestone. There are many therapeutic developers working to address critical patient needs in oncology, auto-immune, regenerative medicine, and other spaces.

Heart disease experts in their own words: ‘This is solvable and this is preventable’

Why aren’t we doing better in the battle against cardiovascular disease? Over the last few months, STAT put that question to nearly a dozen experts

October 15, 2024

GLP-1 Agonists for Diabetes Tied to Lower Hyperkalemia Rates

Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 (DPP-4) inhibitors, a large observational study in

August 13, 2024

Scientists uncover a new doorway for SARS-CoV-2 into human cells

Research identifies the human transferrin receptor as an alternative pathway for SARS-CoV-2 infection, offering potential new targets for COVID-19 therapies.

February 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.